Sientra

Sientra today announced that it received approval from Health Canada to market its smooth surface, high-strength cohesive silicone gel breast implants.

The Santa Barbara, California-based company will market the breast implants in Canada through its local partner Kai Aesthetic. Through the distribution agreement, Sientra will uphold the highest product, safety and service standards to patients and plastic surgeons.

“Health Canada’s approval of Sientra implants in Canada represents another significant milestone for the company as we continue to strategically expand into international markets. As only the third silicone gel breast implant manufacturer approved in Canada—and the first in nearly two decades—we look forward to providing Canadian consumers with the latest generation technology backed by our clinically-proven, unrivaled ten-year safety data, and our industry-leading Platinum20 warranty,” CEO Ron Menezes said in a news release.

“After watching i…

Sientra (NSDQ:SIEN) posted second-quarter results this week that missed the earnings and revenue estimates on Wall Street.

The Santa Barbara, Calif.-based medical aesthetics company reported losses of -$20.1 million, or -35¢ per share, on sales of $20.1 million for the three months ended June 30 for a sales growth of 115.95% compared with Q2 2020.

Sientra’s EPS of -35¢ was 13¢ behind The Street, where analysts were looking for sales of $20.68 million.

“We had an exceptionally strong second quarter, with record Breast Products revenues and total number of accounts reaching the highest in Sientra’s history. We are now solely focused on the plastic surgery market and clearly demonstrating our ability to take market share. Breast augmentation continues to be our strongest growth driver today. Encouragingly, we saw 121% growth in our augmentation sales in the second quarter of 2021 compared to the same quarter in 2019, which significantly outpaced the a…

Sientra (NSDQ:SIEN) today said it appointed Denise Dajles as VP of research and development, effective June 2.

Dajles will lead the Santa Barbara, Calif.-based company’s R&D and medical affairs teams and will report to CEO Ron Menezes.

“We are pleased to welcome Denise to the Sientra management team,” Menezes said in a news release. “With her considerable technical and international expertise, Denise is well-suited to lead our R&D organization as we pursue our goal to be the leader in bringing transformative treatments and technologies to market that progress the art of plastic surgery. I am confident that Denise will provide the leadership and strategic direction to enable us to advance our development of proprietary innovations that improve how plastic surgeons care for their patients.”

Prior to joining the company, Dajles served as senior director of research, development, and innovation at Establishment Labs. She…